Novo Nordisk
Revenue
DKK millions
| Period | Revenue |
|---|---|
| FY 2023 Q1 | DKK 53,367M; Change unavailable vs FY 2022 Q4 |
| FY 2023 Q2 | DKK 54,300M; +1.7% vs FY 2023 Q1 |
| FY 2023 Q3 | DKK 58,731M; +8.2% vs FY 2023 Q2 |
| FY 2023 Q4 | DKK 65,863M; +12.1% vs FY 2023 Q3 |
| FY 2024 Q1 | DKK 65,349M; −0.8% vs FY 2023 Q4 |
| FY 2024 Q2 | DKK 68,060M; +4.1% vs FY 2024 Q1 |
| FY 2024 Q3 | DKK 71,311M; +4.8% vs FY 2024 Q2 |
| FY 2024 Q4 | DKK 85,683M; +20.2% vs FY 2024 Q3 |
| FY 2025 Q1 | DKK 78,087M; −8.9% vs FY 2024 Q4 |
| FY 2025 Q2 | DKK 76,857M; −1.6% vs FY 2025 Q1 |
| FY 2025 Q3 | DKK 74,976M; −2.4% vs FY 2025 Q2 |
| FY 2025 Q4 | DKK 79,144M; +5.6% vs FY 2025 Q3 |
| FY 2026 Q1 | DKK 96,823M; +22.3% vs FY 2025 Q4 |
| FY 2026 Q2 | DKK 78,488M; −18.9% vs FY 2026 Q1 |
Free cash flow
DKK millions
The reported inputs required for this metric are unavailable in the extracted statements for this period.
Net margin
%
| Fiscal period | % |
|---|---|
| FY 2023 Q1 | 37.13% |
| FY 2023 Q2 | 35.78% |
| FY 2023 Q3 | 38.27% |
| FY 2023 Q4 | 33.35% |
| FY 2024 Q1 | 38.88% |
| FY 2024 Q2 | 29.46% |
| FY 2024 Q3 | 38.28% |
| FY 2024 Q4 | 32.95% |
| FY 2025 Q1 | 37.18% |
| FY 2025 Q2 | 34.48% |
| FY 2025 Q3 | 26.68% |
| FY 2025 Q4 | 33.98% |
| FY 2026 Q1 | 50.15% |
| FY 2026 Q2 | 26.74% |
P/E
× · TTM · Daily
Diluted share count is unavailable in the extracted statements for this period.
| Close date | × · TTM · Daily | Financials through |
|---|---|---|
| 2018-02-28 | — | 2017-12-31 |
| 2018-03-28 | — | 2017-12-31 |
| 2018-04-30 | — | 2017-12-31 |
| 2018-05-31 | — | 2017-12-31 |
| 2018-06-29 | — | 2017-12-31 |
| 2018-07-31 | — | 2017-12-31 |
| 2018-08-31 | — | 2017-12-31 |
| 2018-09-28 | — | 2017-12-31 |
| 2018-10-31 | — | 2017-12-31 |
| 2018-11-30 | — | 2017-12-31 |
| 2018-12-28 | — | 2017-12-31 |
| 2019-01-31 | — | 2017-12-31 |
| 2019-02-28 | — | 2017-12-31 |
| 2019-03-29 | — | 2017-12-31 |
| 2019-04-30 | — | 2017-12-31 |
| 2019-05-29 | — | 2017-12-31 |
| 2019-06-28 | — | 2017-12-31 |
| 2019-07-31 | — | 2017-12-31 |
| 2019-08-30 | — | 2017-12-31 |
| 2019-09-30 | — | 2017-12-31 |
| 2019-10-31 | — | 2017-12-31 |
| 2019-11-29 | — | 2017-12-31 |
| 2019-12-30 | — | 2017-12-31 |
| 2020-01-31 | — | 2017-12-31 |
| 2020-02-28 | — | 2019-12-31 |
| 2020-03-31 | — | 2019-12-31 |
| 2020-04-30 | — | 2019-12-31 |
| 2020-05-29 | — | 2019-12-31 |
| 2020-06-30 | — | 2019-12-31 |
| 2020-07-31 | — | 2019-12-31 |
| 2020-08-31 | — | 2019-12-31 |
| 2020-09-30 | — | 2019-12-31 |
| 2020-10-30 | — | 2019-12-31 |
| 2020-11-30 | — | 2019-12-31 |
| 2020-12-30 | — | 2019-12-31 |
| 2021-01-29 | — | 2019-12-31 |
| 2021-02-26 | — | 2020-12-31 |
| 2021-03-31 | — | 2020-12-31 |
| 2021-04-29 | — | 2020-12-31 |
| 2021-05-31 | — | 2020-12-31 |
| 2021-06-30 | — | 2020-12-31 |
| 2021-07-30 | — | 2020-12-31 |
| 2021-08-31 | — | 2020-12-31 |
| 2021-09-30 | — | 2020-12-31 |
| 2021-10-29 | — | 2020-12-31 |
| 2021-11-30 | — | 2020-12-31 |
| 2021-12-30 | — | 2020-12-31 |
| 2022-01-31 | — | 2020-12-31 |
| 2022-02-28 | — | 2020-12-31 |
| 2022-03-31 | — | 2020-12-31 |
| 2022-04-29 | — | 2020-12-31 |
| 2022-05-31 | — | 2020-12-31 |
| 2022-06-30 | — | 2020-12-31 |
| 2022-07-29 | — | 2020-12-31 |
| 2022-08-31 | — | 2020-12-31 |
| 2022-09-30 | — | 2020-12-31 |
| 2022-10-31 | — | 2020-12-31 |
| 2022-11-30 | — | 2020-12-31 |
| 2022-12-30 | — | 2020-12-31 |
| 2023-01-31 | — | 2020-12-31 |
| 2023-02-28 | — | 2020-12-31 |
| 2023-03-31 | — | 2020-12-31 |
| 2023-04-28 | — | 2020-12-31 |
| 2023-05-31 | — | 2020-12-31 |
| 2023-06-30 | — | 2020-12-31 |
| 2023-07-31 | — | 2020-12-31 |
| 2023-08-31 | — | 2020-12-31 |
| 2023-09-29 | — | 2020-12-31 |
| 2023-10-31 | — | 2020-12-31 |
| 2023-11-30 | — | 2020-12-31 |
| 2023-12-29 | — | 2020-12-31 |
| 2024-01-31 | — | 2020-12-31 |
| 2024-02-29 | — | 2023-12-31 |
| 2024-03-27 | — | 2023-12-31 |
| 2024-04-30 | — | 2023-12-31 |
| 2024-05-31 | — | 2023-12-31 |
| 2024-06-28 | — | 2023-12-31 |
| 2024-07-31 | — | 2023-12-31 |
| 2024-08-30 | — | 2023-12-31 |
| 2024-09-30 | — | 2023-12-31 |
| 2024-10-31 | — | 2023-12-31 |
| 2024-11-29 | — | 2023-12-31 |
| 2024-12-30 | — | 2023-12-31 |
| 2025-01-31 | — | 2023-12-31 |
| 2025-02-28 | — | 2023-12-31 |
| 2025-03-31 | — | 2023-12-31 |
| 2025-04-30 | — | 2023-12-31 |
| 2025-05-28 | — | 2023-12-31 |
| 2025-06-30 | — | 2023-12-31 |
| 2025-07-31 | — | 2023-12-31 |
| 2025-08-29 | — | 2023-12-31 |
| 2025-09-30 | — | 2023-12-31 |
| 2025-10-31 | — | 2023-12-31 |
| 2025-11-28 | — | 2023-12-31 |
| 2025-12-30 | — | 2023-12-31 |
| 2026-01-30 | — | 2023-12-31 |
| 2026-02-27 | — | 2025-12-31 |
| 2026-03-31 | — | 2025-12-31 |
| 2026-04-30 | — | 2025-12-31 |
| 2026-05-29 | — | 2025-12-31 |
| 2026-06-30 | — | 2025-12-31 |
| 2026-07-31 | — | 2025-12-31 |
| 2026-08-31 | — | 2025-12-31 |
| 2026-09-25 | — | 2025-12-31 |
ROIC
% · Annual / TTM
| Fiscal period | % · Annual / TTM |
|---|---|
| FY 2023 Q1 | — |
| FY 2023 Q2 | — |
| FY 2023 Q3 | — |
| FY 2023 Q4 | — |
| FY 2024 Q1 | — |
| FY 2024 Q2 | — |
| FY 2024 Q3 | — |
| FY 2024 Q4 | 58.26% |
| FY 2025 Q1 | — |
| FY 2025 Q2 | — |
| FY 2025 Q3 | — |
| FY 2025 Q4 | 37.86% |
| FY 2026 Q1 | — |
| FY 2026 Q2 | — |
Capital allocation
% of tracked cash uses
No validated inputs are available for this chart.
Sources and calculations
Company filings · DKK · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Novo Nordisk.
All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.
SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.
- Revenue
- Reported revenue from company filings.
- Free cash flow
- Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
- Net margin
- Reported net income / revenue × 100.
- P/E
- Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- Capital allocation
- Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.